Table 5.

GEE regression analysis for the number of day-3 good-quality embryos.

Independent variable	POSEIDON group 1			POSEIDON group 2			POSEIDON group 3			POSEIDON group 4
	IRR	95% CI	p-value	IRR	95% CI	p-value	IRR	95% CI	p-value	IRR	95% CI	p-value
GH supplementation
Non-GH	_	_		_	_		_	_		_	_
GH	2.13	1.78–2.56	<0.001*	1.54	1.26–1.89	<0.001*	1.47	1.10–1.98	0.010*	1.00	0.78–1.30	0.971
Age	1.02	0.98–1.06	0.271	1.02	0.98–1.06	0.356	1.00	0.94–1.06	0.890	0.98	0.93–1.03	0.354
BMI	0.98	0.95–1.00	0.093	0.96	0.93–1.00	0.042*	1.02	0.97–1.08	0.377	0.99	0.94–1.05	0.845
AMH	1.06	1.01–1.11	0.014*	0.92	0.84–1.00	0.043*	2.02	1.07–3.83	0.030*	0.88	0.55–1.39	0.573
FSH	0.96	0.91–1.02	0.222	0.94	0.89–0.99	0.031*	1.03	0.98–1.09	0.237	0.99	0.95–1.04	0.756
AFC	0.99	0.97–1.01	0.379	1.04	1.01–1.07	0.012*	1.04	0.97–1.13	0.270	0.99	0.93–1.06	0.792
COH protocol
GnRH antagonist	_	_		_	_		_	_		_	_
GnRH agonist long	1.25	1.01–1.55	0.037*	1.24	0.96–1.60	0.099	1.35	0.94–1.96	0.108	1.74	1.20–2.52	0.004*
GnRH agonist ultra-long	0.57	0.39–0.83	0.003*	1.05	0.73–1.52	0.784	1.28	0.80–2.05	0.311	1.53	0.95–2.46	0.081
GnRH agonist short	1.31	1.01–1.70	0.038*	1.33	1.02–1.74	0.038*	0.76	0.51–1.13	0.178	1.09	0.80–1.48	0.600
Duration of Gn	0.99	0.93–1.04	0.628	1.05	0.98–1.13	0.158	1.02	0.93–1.12	0.642	1.07	0.98–1.17	0.144
Gn dose (per 100 IU)	1.01	0.99–1.02	0.272	1.00	0.99–1.01	0.994	0.99	0.97–1.01	0.219	1.00	1.00–1.00	0.024*

GH, growth hormone; BMI, body mass index; AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; AFC, antral follicle count; COH, controlled ovarian hyperstimulation; GnRH, gonadotropin-releasing hormone; Gn, gonadotropin.

In bold: The values associated with GH.

*indicates statistical significances of p < 0.05.